Nuala Moran

The largest international science project since the Space Station has finally got the go-ahead after ten years of discussions.

The European Union has unveiled a new way of funding R&D that allows it for the first time to pool public and private resources.

Pharmaceutical companies need to replenish their portfolios. But are biologics the way to go? Part 2 of Nuala Moran's report from Düsseldorf.

The German Research Foundation is calling for the urgent revision of the country’s 2002 Stem Cell Act.

Just four out of ten Portuguese firms were actively investing in innovation between 2002 and 2004, according to a new report.

The new system developed over the past six years by Chalmers University of Technology has notched up its first exit.

Big pharma is hungry, and is paying biotechs breathtaking prices to fill its pipelines. This made for a heady atmosphere at BioEurope in Düsseldorf this week.

The European Research Council has confirmed that its first grants will be targeted at young researchers with between two and eight years' postdoctoral experience.

As Intel announced it was closing its research laboratory, Cambridge University announced that a US philanthropist is to fund the formation of another. Rather than disruptive computing technologies, the new institute will probe the beginning of the cosmos.